Skip to main content
Log in

Die Knochendichte kann bei HIV-Patienten schon früh abnehmenachtungsstudien

Osteoporose, Vitamin-D-Mangel und Niereninsuffizienz

  • FORTBILDUNG
  • ÜBERSICHT
  • Published:
MMW - Fortschritte der Medizin Aims and scope

HIV-Patienten haben häufiger eine niedrige Knochendichte, Osteopenie und Osteoporose als nicht HIV-Infizierte, begleitend auch einen Vitamin-D-Mangel und eine Niereninsuffizienz. Daher lohnt es sich, bei diesen Patienten schon relativ frühzeitig an die Messung der Knochendichte zu denken.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Weinberg,M., Schambelan M: Bone and calcium disorders in HIV-infected patients. www.uptodate.com 2012 assessed 03.02.2012

  2. Borderi et al: Metabolic bone disease in HIV infection. AIDS 2009; 23:1297

    Article  PubMed  Google Scholar 

  3. Brown TT et al: Antiretroviral therapy and the prevalence of osteopenia and osteoporose: a metaanalytic review. AIDS 2006; 20:2165

    Article  PubMed  Google Scholar 

  4. Bonjoch A et al: High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 2010; 24: 2827

    Article  PubMed  Google Scholar 

  5. Cazanave C et al: Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008; 22: 395

    Google Scholar 

  6. Triant VA et al: Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected Patients in a large US healthcare system. J.Clin Endocrinol Metab 2008; 93:3499

    Article  PubMed  CAS  Google Scholar 

  7. McComsey GA et al: Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and management. J Int Assoc Physicians AIDS care (Chic) 2004; 3: 86

    Article  Google Scholar 

  8. Manolagas SC, Jilka RL: Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332: 305

    Article  PubMed  CAS  Google Scholar 

  9. Martin K et al: Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitaine cohort (1999–2002). HIV Medicine 2004; 5: 421

    Article  PubMed  CAS  Google Scholar 

  10. Gibellini D et al: HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol 2008; 80:1507

    Article  PubMed  CAS  Google Scholar 

  11. Collier J: Bone disorders in chronic liver disease. Hepatology 2007; 46: 1271

    Article  PubMed  CAS  Google Scholar 

  12. Yin MT et al: Fracture incidence in HIV-infected women: results from the Women’s Interagency HIV Study. AIDS 2010; 24: 2679

    Article  PubMed  Google Scholar 

  13. Grund B et al: Continuous antiretrovirus therapy decreases bone mineral density. AIDS 2009; 23: 1519

    Article  PubMed  CAS  Google Scholar 

  14. Jacobson DL et al: Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr 2008; 49: 298

    Article  PubMed  CAS  Google Scholar 

  15. Gallant JE et al: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. JAMA 2004; 292: 191

    Article  PubMed  CAS  Google Scholar 

  16. http://www.retroconference.org/2009/Abstracts/33890.htm (accessed 02.02.2012)

  17. McComsey GA et al: Bone mineral density and fractures in antiretroviral-naïve persons randomized to receive abacavir-lamivudine of tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG 5202. J Infect Dis 2011; 203: 1791

    Article  PubMed  CAS  Google Scholar 

  18. Duvivier C et al: Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naïve patients. AIDS 2009; 23: 817

    Article  PubMed  Google Scholar 

  19. Nolan D et al: Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001; 15: 1275

    Article  PubMed  CAS  Google Scholar 

  20. Arnsten JH et al: Decreases bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007; 21: 617

    Article  PubMed  Google Scholar 

  21. Van Den Bout-Van Den Beukel CJ et al: Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008; 24: 1375

    Article  Google Scholar 

  22. Kühne CA et al: Bone and mineral metabolism in human immunodeficiency virus infection. J Bone Miner Res 2001; 16:2

    Article  PubMed  Google Scholar 

  23. Mueller NJ et al: High prevalence of severe vitamin D deficiency in combined therapy-naïve and successfully treated Swiss HIV patients. AIDS 2010; 24: 1127

    Article  PubMed  CAS  Google Scholar 

  24. Cooper RD et al: Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51: 496

    Article  PubMed  CAS  Google Scholar 

  25. Fernandez-Fernandez B et al: Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011; 2011: 354908, Epub 2011, Jun 7

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Frank-Detlef Goebel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goebel, FD. Die Knochendichte kann bei HIV-Patienten schon früh abnehmenachtungsstudien. MMW - Fortschritte der Medizin 154, 37–40 (2012). https://doi.org/10.1007/s15006-012-0625-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-012-0625-y

Keywords - Osteoporosis, vitamin D deficiency and renale failure

Navigation